Skip to content
Accessibility help
Search NICE…
Menu
Sign in
Guidance
Standards and indicators
Clinical Knowledge Summaries (CKS)
British National Formulary (BNF)
BNF for Children (BNFC)
Life sciences
More from NICE
Home
NICE guidance
Awaiting development
Awaiting development: Guidance and quality standards
Skip to filters
Skip to results
Published
In consultation
In development
Deferred
Awaiting development
Topic prioritisation
Filter (1 applied)
Skip to results
Keyword or reference number
Keyword or reference number
Apply filter
Type
Type
Guidance (86)
Guidance programme
Guidance programme
HealthTech guidance (2)
Technology appraisal guidance (84)
Apply filters
Showing 61 to 70 of 86
Keyword or reference number: cancer
`Remove $Keyword or reference number: cancer filter`
Guidance and quality standards awaiting development
Title
Type
Sacituzumab govitecan for untreated PD-L1-negative triple-negative advanced breast
cancer
[ID6433]
Technology appraisal guidance
Savolitinib with osimertinib for treating EGFR-mutated MET-overexpressed or amplified advanced non-small-cell lung
cancer
after osimertinib [ID6494]
Technology appraisal guidance
Serplulimab with chemotherapy for neoadjuvant and adjuvant treatment of untreated gastric
cancer
[ID6760]
Technology appraisal guidance
Sevabertinib for untreated HER2-positive advanced non-small-cell lung
cancer
[ID6616]
Technology appraisal guidance
Sigvotatug vedotin for Non-small-cell lung
cancer
[ID6718]
Technology appraisal guidance
Sotorasib with pemetrexed and carboplatin for untreated KRAS G12C mutation-positive advanced non-small-cell lung
cancer
[ID6741]
Technology appraisal guidance
Sugemalimab for consolidation treatment of locally advanced or unresectable non-small-cell lung
cancer
after chemoradiotherapy [ID6737]
Technology appraisal guidance
Talazoparib with enzalutamide for untreated hormone-sensitive metastatic prostate
cancer
with a homologous recombination repair mutation [ID6460]
Technology appraisal guidance
Tarlatamab for maintenance treatment of extensive-stage small-cell lung
cancer
[ID6749]
Technology appraisal guidance
Tarlatamab for treating limited-stage small-cell lung
cancer
after chemoradiotherapy [ID6748]
Technology appraisal guidance
Previous page
1
…
5
6
Current page
7
8
9
Page
7
of
9
Next page
Results per page
10
25
50
All
Back to top